Proceedings of the 13th International Conference on Thrombosis and Hemostasis Issues in Cancer, 2026
Vol. 5 No. s1 (2026)
Bleeding in cancer: epidemiological aspects
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 16 April 2026
0
Views
0
Downloads
Authors
Cancer is accompanied with significant changes in hemostasis caused by both the underlying malignancy and its treatment, which increases the risk of thrombotic and bleeding consequences. While cancer-related thrombosis has been extensively studied, bleeding remains relatively unexplored, despite its major contribution to morbidity and mortality in this population. The epidemiology of bleeding in cancer patients is complicated and difficult to assess. Multiple linked factors influence risk, such as tumor kind, disease stage, treatment modalities, patient clinical context, and concomitant diseases. Furthermore, bleeding risk varies over time, reflecting dynamic changes in tumor load, treatment approaches, and host variables. As a result, estimates of incidence and prevalence vary greatly depending on the population investigated, the date of cancer diagnosis, and the bleeding definitions used. The type and dosage of anticoagulant medication may also influence this risk. These problems underline the importance of a more holistic approach to bleeding in cancer care. Bleeding prevention should be prioritized in future cancer-related venous thromboembolism management regimens. To lower the clinical burden of cancer and enhance patient outcomes, we must advance our understanding of bleeding epidemiology.
Downloads
Download data is not yet available.
Citations
1. Mantha S. Bleeding disorders associated with cancer. Cancer Treat Res 2019;179:191-203. DOI: https://doi.org/10.1007/978-3-030-20315-3_13
2. Englisch C, Vladic N, Ay C. Bleeding risk in patients with cancer. Hamostaseologie 2025;45:188-203. DOI: https://doi.org/10.1055/a-2347-6507
3. Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med 2019;380:711-9. DOI: https://doi.org/10.1056/NEJMoa1814468
4. Khorana AA, Soff GA, Kakkar AK, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med 2019;380:720-8. DOI: https://doi.org/10.1056/NEJMoa1814630
5. Li A, Kuderer NM, Garcia DA, et al. Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: A systematic review and meta-analysis. J Thromb Haemost 2019;17:2141-51. DOI: https://doi.org/10.1111/jth.14613
6. Agnelli G, George DJ, Kakkar AK, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012;366:601-9. DOI: https://doi.org/10.1056/NEJMoa1108898
7. Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009;10:943-9. DOI: https://doi.org/10.1016/S1470-2045(09)70232-3
8. Khorana AA, Francis CW, Kuderer NM, et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Thrombosis Res 2017;151:89-95. DOI: https://doi.org/10.1016/j.thromres.2017.01.009
9. Pelzer U, Opitz B, Deutschinoff G, et al. Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. J Clin Oncol 2015;33:2028-34. DOI: https://doi.org/10.1200/JCO.2014.55.1481
10. Englisch C, Moik F, Steiner D, et al. Bleeding events in patients with cancer: incidence, risk factors, and impact on prognosis in a prospective cohort study. Blood 2024;144:2349-59. DOI: https://doi.org/10.1182/blood.2024025362
11. Agnelli G, Muñoz A, Franco L, et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thromb Haemost 2022;122:796-807. DOI: https://doi.org/10.1055/s-0041-1735194
12. Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020;382:1599-607. DOI: https://doi.org/10.1056/NEJMoa1915103
13. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost 2015;13:2187-91. DOI: https://doi.org/10.1111/jth.13153
14. Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018;378:615-24. DOI: https://doi.org/10.1056/NEJMoa1711948
15. Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018;36:2017-23. DOI: https://doi.org/10.1200/JCO.2018.78.8034
16. Frere C, Farge D, Schrag D, et al. Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials. J Hematol Oncol 2022;15:69. DOI: https://doi.org/10.1186/s13045-022-01289-1
17. Yau CE, Low CE, Ong NY, et al. Non-vitamin K antagonist oral anticoagulants versus low molecular weight heparin for cancer-related venous thromboembolic events: individual patient data meta-analysis. Cancers (Basel) 2023;15:5887. DOI: https://doi.org/10.3390/cancers15245887
18. Castellicci L, Chen V, Kovacs MJ, et al. 2025 Late breakthrough abstracts. Res Pract Thromb Haemost 2025;9:102931. DOI: https://doi.org/10.1016/j.rpth.2025.102931
19. Trujillo-Santos J, Nieto JA, Ruiz-Gamietea A, et al. Bleeding complications associated with anticoagulant therapy in patients with cancer. Thromb Res 2010;125:S58-61. DOI: https://doi.org/10.1016/S0049-3848(10)70015-3
20. McBane RD 2nd, Loprinzi CL, Zemla T, et al. Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial. J Thromb Haemost 2024;22:1704-14. DOI: https://doi.org/10.1016/j.jtha.2024.03.011
21. Mahé I, Carrier M, Mayeur D, et al. Extended reduced-dose apixaban for cancer-associated venous thromboembolism. N Engl J Med 2025;392:1363-73. DOI: https://doi.org/10.1056/NEJMoa2416112
22. Angelini DE, Radivoyevitch T, McCrae KR, Khorana AA. Bleeding incidence and risk factors among cancer patients treated with anticoagulation. Am J Hematol 2019;94:780-5. DOI: https://doi.org/10.1002/ajh.25494
23. Nishimoto Y, Yamashita Y, Kim K, et al. Risk factors for major bleeding during anticoagulation therapy in cancer-associated venous thromboembolism-From the COMMAND VTE Registry. Circ J 2020;84:2006-14. DOI: https://doi.org/10.1253/circj.CJ-20-0223
24. Streiff MB, Milentijevic D, McCrae K, et al. Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer. Am J Hematol 2018;93:664-71. DOI: https://doi.org/10.1002/ajh.25059
25. Khan F, Tritschler T, Marx CE, et al. Predictors of recurrent venous thromboembolism and bleeding in patients with cancer: a meta-analysis. Eur Heart J 2025;ehaf453. Online Ahead of Print. DOI: https://doi.org/10.1093/eurheartj/ehaf453
26. Loncharich A, Gage BF, Luo S, et al. Risk factors for anticoagulant-related bleeding in cancer: traditional and cancer-specific factors. Blood Vessel Thromb Hemost 2026;3:100116. DOI: https://doi.org/10.1016/j.bvth.2025.100116
27. McBane RD, 2nd, Wysokinski WE, Le-Rademacher JG, et al.Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost 2020;18: 411-21. DOI: https://doi.org/10.1111/jth.14662
28. Schrag D, Uno H, Rosovsky R, et al. Direct Oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial. JAMA 2023;329:1924-33. DOI: https://doi.org/10.1001/jama.2023.7843
29. Planquette B, Bertoletti L, Charles-Nelson A, et al. Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial. Chest 2022;161:781-90. DOI: https://doi.org/10.1016/j.chest.2021.09.037
30. Elwood PC, Morgan G, Delon C, et al. Aspirin and cancer survival: a systematic review and meta-analyses of 118 observational studies of aspirin and 18 cancers. Ecancermedicalscience 2021;15:1258. DOI: https://doi.org/10.3332/ecancer.2021.1258
31. Feher A, Kampaktsis PN, Parameswaran R, et al. Aspirin is associated with improved survival in severely thrombocytopenic cancer patients with acute myocardial infarction. Oncologist 2017;22:213-21. DOI: https://doi.org/10.1634/theoncologist.2016-0110
32. Palumbo A, Cavo M, Bringhen S, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a Phase III, open-label, randomized trial. J Clin Oncol 2011;29:986-93. DOI: https://doi.org/10.1200/JCO.2010.31.6844
33. Campos CM, Mehran R, Capodanno D, et al. Risk Burden of cancer in patients treated with abbreviated dual antiplatelet therapy after PCI: Analysis of multicenter controlled high-bleeding risk trials. Circ Cardiovasc Interv 2024;17:e013000. DOI: https://doi.org/10.1161/CIRCINTERVENTIONS.122.013000
34. Potts JE, Iliescu CA, Lopez Mattei JC, et al. Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States. Eur Heart J 2018;40:1790-800. DOI: https://doi.org/10.1093/eurheartj/ehy769
35. Roule V, Verdier L, Blanchart K, et al. Systematic review and meta-analysis of the prognostic impact of cancer among patients with acute coronary syndrome and/or percutaneous coronary intervention. BMC Cardiovasc Disord 2020;20:38. DOI: https://doi.org/10.1186/s12872-020-01352-0
36. Nishikawa T, Morishima T, Fujii Y, et al. Prognostic impact of cancer activity on clinically relevant bleeding events after percutaneous coronary intervention. J Med Invest 2021;68:29-37. DOI: https://doi.org/10.2152/jmi.68.29
37. Kanenawa K, Yamaji K, Morinaga T, et al. Clinical outcomes after percutaneous coronary intervention in patients with cancer. Circ J 2021;85:837-46. DOI: https://doi.org/10.1253/circj.CJ-20-1119
38. Valeriani E, Porreca E, Weitz JI, et al. Impact of concomitant antiplatelet therapy on the efficacy and safety of direct oral anticoagulants for acute venous thromboembolism: Systematic review and meta-analysis. J Thromb Haemost 2020;18:1661-71. DOI: https://doi.org/10.1111/jth.14807
39. Saad M, Mallick R, Hill D, et al. Impact of concurrent antiplatelet/NSAID use on the safety and efficacy of thromboprophylaxis with apixaban in patients with cancer: A post-hoc analysis of the AVERT trial. Blood 2025;146:741. DOI: https://doi.org/10.1182/blood-2025-741
40. Xiong W, Deng Z, Cheng Y, et al. Adjuvant therapeutic efficacy of low-dose aspirin on short-term outcomes of patients with cancer-associated venous thromboembolism. BMC Med 2025;23:444. DOI: https://doi.org/10.1186/s12916-025-04284-8
41. Kraaijpoel N, Di Nisio M, Mulder FI, et al. Clinical impact of bleeding in cancer-associated venous thromboembolism: Results from the Hokusai VTE cancer study. Thromb Haemost 2018;118:1439-49. DOI: https://doi.org/10.1055/s-0038-1667001
42. Howlett J, Benzenine E, Cottenet J, et al. Could venous thromboembolism and major bleeding be indicators of lung cancer mortality? A nationwide database study. BMC Cancer 2020;20:461. DOI: https://doi.org/10.1186/s12885-020-06930-1
43. Liang Z, Mao J, Xie J, et al. Risk factors for recurrence and bleeding in colorectal cancer patients with cancer-associated venous thrombembolism. Front Oncol 2025;15;1648003. DOI: https://doi.org/10.3389/fonc.2025.1648003
44. Mahmoud A, Luo S, Gage BF, et al. Association between anticoagulant-related bleeding and mortality in patients with solid tumors and cancer-associated venous thromboembolism. Am J Hematol 2025;100:535-8. DOI: https://doi.org/10.1002/ajh.27588
45. Wang TF, Luo S, Gage BF, et al. Association between anticoagulant-related bleeding and mortality in patients with hematological malignancies and cancer-associated venous thromboembolism. Thrombosis Res 2025; 248:109284. DOI: https://doi.org/10.1016/j.thromres.2025.109284
46. Sigüenza P, López-Núñez JJ, Falgá C, et al. Enoxaparin for long-term therapy of venous thromboembolism in patients with cancer and renal insufficiency. Thromb Haemost 2023;124:363-73. DOI: https://doi.org/10.1055/a-2191-7510
47. Abdulla A, Davis WM, Ratnaweera N, et al. A meta-analysis of case fatality rates of recurrent venous thromboembolism and major bleeding in patients with cancer. Thromb Haemost 2020;120:702-13. DOI: https://doi.org/10.1055/s-0040-1708481
48. Poénou G, Tolédano E, Helfer H, et al. In search of the appropriate anticoagulant-associated bleeding risk assessment model for cancer-associated thrombosis patients. Cancers (Basel) 2022;14:1937. DOI: https://doi.org/10.3390/cancers14081937
49. de Winter MA, Dorresteijn JAN, Ageno W, et al. Estimating bleeding risk in patients with cancer-associated thrombosis: evaluation of existing risk scores and development of a new risk score. Thromb Haemost 2022;122:818-29. DOI: https://doi.org/10.1055/s-0041-1735251
50. Hussaini P, Larsen TL, Ghanima W, Dahm AEA. Risk factors for bleeding in cancer patients treated with conventional dose followed by low-dose apixaban for venous thromboembolism. Thromb Haemost 2024;124:351-62. DOI: https://doi.org/10.1055/a-2188-8773
51. Vedovati MC, Talerico R, Sacco C, et al. Major bleeding risk assessment in patients with cancer-associated venous thromboembolism treated with DOACs: data from a multicenter cohort. Thromb Haemost 2026;126:276-86. DOI: https://doi.org/10.1055/a-2605-9015
52. Bauersachs R, Lee AYY, Kamphuisen PW, et al. Renal impairment, recurrent venous thromboembolism and bleeding in cancer patients with acute venous thromboembolism—Analysis of the CATCH Study. Thromb Haemost 2018;118:914-21. DOI: https://doi.org/10.1055/s-0038-1641150
53. Kooiman J, den Exter PL, Cannegieter SC, et al. Impact of chronic kidney disease on the risk of clinical outcomes in patients with cancer‐associated venous thromboembolism during anticoagulant treatment. J Thromb Haemost 2013;11:1968-76. DOI: https://doi.org/10.1111/jth.12411
54. Monreal M, Falgá C, Valdés M, et al. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. J Thromb Haemost 2006;4: 950-6. DOI: https://doi.org/10.1111/j.1538-7836.2006.02082.x
55. Becattini C, Bauersachs R, Maraziti G, et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica 2022;107:1567-76. DOI: https://doi.org/10.3324/haematol.2021.279072
56. Shahbar A, Noor A, Hakami AY, et al. Venous thromboembolism in cancer: predictors of recurrence and bleeding in patients on direct oral anticoagulants. J Clin Med 2025;14:752. DOI: https://doi.org/10.3390/jcm14082752
57. Wu S, Wang H, Li C, et al. Efficacy and safety of direct oral anticoagulants for preventing venous thromboembolism in hospitalized cancer patients: a national multicenter retrospective cohort study. Front Pharmacol 2024;15:1373635. DOI: https://doi.org/10.3389/fphar.2024.1373635
58. Kimpton M, Wells PS, Carrier M. Apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients receiving chemotherapy: Rational and design of the AVERT trial. Thromb Res 2018;164:S124-s9. DOI: https://doi.org/10.1016/j.thromres.2018.01.018
59. Martinez C, Katholing A, Wallenhorst C, Cohen AT. Prediction of significant bleeding during vitamin K antagonist treatment for venous thromboembolism in outpatients. Br J Haematol 2020;189:524-33. DOI: https://doi.org/10.1111/bjh.16383
60. Wysokinski WE, Houghton DE, Vlazny DT, et al. Influence of primary cancer site on clinical outcomes of anticoagulation for associated venous thromboembolism. Thromb Res 2023;221:37-44. DOI: https://doi.org/10.1016/j.thromres.2022.11.005
61. Pastori D, Marang A, Bisson A, et al. Bleeding risk prediction in a large cohort of patients with atrial fibrillation and cancer: a nationwide cohort study. Eur Heart J 2022;43;ehac544.620. DOI: https://doi.org/10.1093/eurheartj/ehac544.620
62. Frere C, Font C, Esposito F, et al. Incidence, risk factors, and management of bleeding in patients receiving anticoagulants for the treatment of cancer-associated thrombosis. Support Care Cancer 2022;30 2919-31. DOI: https://doi.org/10.1007/s00520-021-06598-8
63. Kamphuisen PW, Lee AYY, Meyer G, et al. Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study. J Thromb Haemost 2018;16:1069-77. DOI: https://doi.org/10.1111/jth.14007
64. Vedovati MC, Giustozzi M, Munoz A, et al. Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolism. Eur J Intern Med 2023;112:29-36. DOI: https://doi.org/10.1016/j.ejim.2023.02.003
65. Giustozzi M, Proietti G, Becattini C, et al. ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis. Blood Adv 2022;6:4873-83. DOI: https://doi.org/10.1182/bloodadvances.2022008086
66. Self EM, Bumpous J, Ziegler C, et al. Risk factors for hemorrhage after chemoradiation for oropharyngeal squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg 2013;139:356-61. DOI: https://doi.org/10.1001/jamaoto.2013.103
67. Je Y, Schutz FA, Choueiri TK. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 2009;10:967-74. DOI: https://doi.org/10.1016/S1470-2045(09)70222-0
68. Verso M, Munoz A, Agnelli G. Bleeding risk with concomitant administration of VEGF-TKIs and anticoagulant agents. Semin Oncol 2023;50:67-70. DOI: https://doi.org/10.1053/j.seminoncol.2023.05.002
69. Xiao B, Wang W, Zhang D. Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials. Onco Targets Ther 2018;11:5059-74. DOI: https://doi.org/10.2147/OTT.S166151
70. Shatzel JJ, Olson SR, Tao DL, et al. Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. J Thromb Haemost 2017;15:835-47. DOI: https://doi.org/10.1111/jth.13651
71. Caron F, Leong DP, Hillis C, et al. Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis. Blood Adv 2017;1:772-8. DOI: https://doi.org/10.1182/bloodadvances.2016001883
72. Samuelson Bannow BT, Lee A, Khorana AA, et al. Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH. J Thromb Haemost 2018;16 1246-9. DOI: https://doi.org/10.1111/jth.14015
73. Adelborg K, Veres K, Horvath-Puho E, et al. Risk and adverse clinical outcomes of thrombocytopenia among patients with solid tumors-a Danish population-based cohort study. Br J Cancer 2024;130:1485-92. DOI: https://doi.org/10.1038/s41416-024-02630-w
74. Di Micco P, Ruiz-Gimenez N, Nieto JA, et al. Platelet count and outcome in patients with acute venous thromboembolism. Thromb Haemost 2013;110:1025-34. DOI: https://doi.org/10.1160/TH13-04-0352
75. Wang TF, Carrier M, Carney BJ, et al. Anticoagulation management and related outcomes in patients with cancer-associated thrombosis and thrombocytopenia: A systematic review and meta-analysis. Thromb Res 2023;227:8-16. DOI: https://doi.org/10.1016/j.thromres.2023.05.012
76. Sallah S, Wan JY, Nguyen NP, et al. Disseminated intravascular coagulation in solid tumors: clinical and pathologic study. Thromb Haemost 2001;86:828-33. DOI: https://doi.org/10.1055/s-0037-1616139
77. Franchini M, Di Minno MN, Coppola A. Disseminated intravascular coagulation in hematologic malignancies. Semin Thromb Hemost 2010;36:388-403. DOI: https://doi.org/10.1055/s-0030-1254048
78. Levi M. Disseminated intravascular coagulation in cancer: an update. Semin Thromb Hemost 2019;45:342-7. DOI: https://doi.org/10.1055/s-0039-1687890
79. Liu R, Lv Y, Hong F, et al. A comprehensive analysis of coagulopathy during anti-B cell maturation antigen chimeric antigen receptor-T therapy in multiple myeloma, a retrospective study based on LEGEND-2. Hematol Oncol 2023;41:704-17. DOI: https://doi.org/10.1002/hon.3155
80. Wang Y, Qi K, Cheng H, et al. Coagulation disorders after chimeric antigen receptor T cell therapy: analysis of 100 patients with relapsed and refractory hematologic malignancies. Biol Blood Marrow Transplant 2020;26:865-75. DOI: https://doi.org/10.1016/j.bbmt.2019.11.027
81. Johnsrud A, Craig J, Baird JH, Spiegel JY, et al. Bleeding and thrombosis are associated with endothelial dysfunction in CAR-T cell therapy and are increased in patients experiencing neurologic toxicity. Blood 2020;136:32-3. DOI: https://doi.org/10.1182/blood-2020-142218
82. Mei H, Chen F, Han Y, et al. Chinese expert consensus on the management of chimeric antigen receptor T cell therapy-associated coagulopathy. Chin Med J 2022;135:1639-41. DOI: https://doi.org/10.1097/CM9.0000000000002288
83. Napolitano M, Siragusa S, Mancuso S, Kessler CM. Acquired haemophilia in cancer: A systematic and critical literature review. Haemophilia 2018;24:43-56. DOI: https://doi.org/10.1111/hae.13355
84. Franchini M, Targher G, Manzato F, Lippi G. Acquired factor VIII inhibitors in oncohematology: a systematic review. Crit Rev Oncol Hematol 2008;66:194-9. DOI: https://doi.org/10.1016/j.critrevonc.2007.12.004
85. Li Y, Jiang H, Luo L, Mei H. Immunotherapy-associated hemostatic abnormalities: bleeding and thrombotic complications. Ann Hematol 2025;104:3537-51. DOI: https://doi.org/10.1007/s00277-025-06482-z
86. Menegatti M, Biguzzi E, Peyvandi F. Management of rare acquired bleeding disorders. Hematology 2019;2019:80-7. DOI: https://doi.org/10.1182/hematology.2019000066
87. Federici AB, Rand JH, Bucciarelli P, et al. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost 2000;84:345-9. DOI: https://doi.org/10.1055/s-0037-1614018
88. Eby C. Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias. Br J Haematol 2009;145:151-63. DOI: https://doi.org/10.1111/j.1365-2141.2008.07577.x
89. Furie B, Greene E, Furie BC. Syndrome of acquired factor X deficiency and systemic amyloidosis; in vivo studies of the metabolic fate of factor X. N Engl J Med 1977;297:81-5. DOI: https://doi.org/10.1056/NEJM197707142970203
90. Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (anticoagulation and risk factors in atrial fibrillation) study. J Am Coll Cardiol 2011;58:395-401. DOI: https://doi.org/10.1016/j.jacc.2011.03.031
91. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093-100. DOI: https://doi.org/10.1378/chest.10-0134
92. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006;151:713-9. DOI: https://doi.org/10.1016/j.ahj.2005.04.017
93. O'Brien EC, Simon DN, Thomas LE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J 2015;36:3258-64. DOI: https://doi.org/10.1093/eurheartj/ehv476
94. Ruiz-Gimenez N, Suarez C, Gonzalez R, et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008;100:26-31. DOI: https://doi.org/10.1160/TH08-03-0193
95. Klok FA, Hosel V, Clemens A, et al. Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. Eur Respir J 2016;48:1369-76. DOI: https://doi.org/10.1183/13993003.00280-2016
96. Sanfilippo K, Luo S, Gage B. Oral Communication Abstract. OC 16.5 - Available risk scores modestly predict hemorrhage in patients with cancer-associated thrombosis (CAT). Res Pract Thromb Haemost 2022;6:e12787.
97. Sanfilippo KM, Yan Y, Carrier M, Gage BF. Discriminating risk of anticoagulant-related bleeding in ambulatory cancer patients on thromboprophylaxis. Blood 2023;142:567. DOI: https://doi.org/10.1182/blood-2023-190795
98. Cohen AT, Wallenhorst C, Choudhuri S, et al. A novel risk prediction score for clinically significant bleeding in patients anticoagulated for venous thromboembolism with active cancer. Thromb Haemost 2024;124 324-36. DOI: https://doi.org/10.1055/a-2145-7238
99. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74:229-63. DOI: https://doi.org/10.3322/caac.21834
100. Mahajan A, Brunson A, Adesina O, et al. The incidence of cancer-associated thrombosis is increasing over time. Blood Adv 2022;6:307-20. DOI: https://doi.org/10.1182/bloodadvances.2021005590
101. Li A, Carlson JJ, Kuderer NM, et al. Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States. Cancer 2020;126:1736-48. DOI: https://doi.org/10.1002/cncr.32724
102. Poénou G, Tolédano E, Helfer H, et al. Assessment of bleeding risk in cancer patients treated with anticoagulants for venous thromboembolic events. Front Cardiovasc Med 2023;10:1132156. DOI: https://doi.org/10.3389/fcvm.2023.1132156
103. Sanfilippo KM, Yan Y, Luo S, et al. Elimination of modifiable risk factors for anticoagulant-related bleeding in patients with cancer reduces the probability of bleeding. Blood 2024;144 814. DOI: https://doi.org/10.1182/blood-2024-206168
How to Cite
1.
Bria K, Mahmoud A, Sanfilippo KM. Bleeding in cancer: epidemiological aspects. Bleeding Thromb Vasc Biol [Internet]. 2026 Apr. 16 [cited 2026 Apr. 17];5(s1). Available from: https://www.btvb.org/btvb/article/view/453
Copyright (c) 2026 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Most read articles by the same author(s)
- Kristen M. Sanfilippo, Tzu-Fei Wang, Venous thromboembolism and mortality in patients with hematological malignancies , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024)
- Tzu-Fei Wang, Kristen M. Sanfilippo, Marc Carrier, Pharmacokinetic interactions between anticancer drugs and direct oral anticoagulants: clinical implications for safe anticoagulation , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
